-+ 0.00%
-+ 0.00%
-+ 0.00%

Immix Biopharma Inc publishes presentation highlighting leadership in relapsed and refractory AL Amyloidosis and promising NXC201 clinical data

Reuters·10/08/2025 21:49:07

Please log in to view news